Home
News
News archive
Diamond Information


home > news Nasal spray depression treatment on track for FDA approval

Nasal spray depression treatment on track for FDA approval




A ketamine-like drug for treatment-resistant depression was backed by a US Food and Drug Administration advisory committee on Tuesday. If it is then approved by the FDA, the drug -- called esketamine -- may provide a new option for patients with major depressive disorder who have tried at least two other antidepressants without success.



Click Here to read the entire article...



Find this article in Google